Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
about
Generalised anxiety disorderCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersExercise as Treatment for Anxiety: Systematic Review and Analysis.Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trialsGeneralised anxiety disorder.Why do some promising brain-stimulation devices fail the next steps of clinical development?A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)Pharmacological treatment for generalized anxiety disorder in adults: an update.Escitalopram therapy for major depression and anxiety disorders.Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trialWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Pregabalin influences insula and amygdala activation during anticipation of emotional images.Pharmacotherapy of anxiety disorders: a critical reviewEscitalopram in the treatment of generalized anxiety disorder.Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.Managing depressive and anxiety disorders with escitalopram.Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopause.The diagnosis and treatment of generalized anxiety disorder.The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALSEscitalopram in the treatment of obsessive-compulsive disorder.The therapeutic potential of escitalopram in the treatment of panic disorder.Escitalopram for the treatment of major depression and anxiety disorders.The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting.Predictors of premature discontinuation of treatment in multiple disease statesPharmacological treatment of generalized anxiety disorder.Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.The cost effectiveness of pharmacological treatments for generalized anxiety disorder.The impact of medication on health-related quality of life in patients with generalized anxiety disorder.Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines.Quality of life in depression and anxiety: does it matter?An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.Generalizability of clinical trial results for generalized anxiety disorder to community samples.The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm".Anxiolytic and panicolytic effects of escitalopram in the elevated T-maze.An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.
P2860
Q26863288-FC583154-DC58-4169-89CD-88C5A238CB79Q27009995-754D1418-D186-4733-A27E-BFEC7050F39FQ27693304-5F43D77B-84E4-4A7B-BB6A-5D91F363D912Q28069524-8444AA01-C608-4DAC-85AD-B8ECAAFD5F24Q33446789-473E1595-8DC3-43D7-AEF2-A2B338E8E18CQ33519672-38B8F146-DEEB-4D43-AFC2-EFFAC7269824Q34183517-9442C561-A185-42B0-998F-5B02640C03C1Q34484276-B33ECBAC-DFD8-4853-AC96-B180F6A08FC1Q34685982-4F6FC02E-F50A-4691-971D-0AE6AE200DD0Q34853281-1DF558C7-68E1-49FF-B243-1F6289194F6BQ34865036-806BD5EC-9192-493D-B77E-6C253DB8A782Q34988442-4DA73B67-AD48-49D8-AEB4-956F487F75A5Q35686859-5D008145-23A2-48C1-B802-98F440367A7BQ36198579-3CBA176A-8ABE-4B0A-9C33-342D2AD6DF54Q36205791-6FDF2E78-DBE9-4863-B64B-2CC79A7D07DAQ36407369-ED375F77-28EB-4AE1-AEFA-0D36C8B082A1Q36606190-D0586DE2-E165-40B7-BA37-1EBE5DC78C35Q36692651-EBCCA890-4F19-492B-B33E-A4FEF372BC82Q36837462-8AB2B034-5A72-4AB2-B658-BDDD9B6740B2Q36960563-82AC9CDE-2C97-41F6-A1B0-336F56C60BF2Q37041164-E0276BA9-A66E-40CF-A803-D6793B243169Q37111879-7E7DA570-FF4E-4394-AB60-37402FFC0582Q37129822-BDCC12FD-7743-431D-A79F-9FA3ABA25E47Q37139768-B4818D11-F757-49A1-B737-57E0021314DDQ37207545-F484186B-0763-4BAB-BCDB-E95FAF07C9C0Q37219387-1D509F10-30E3-4349-BC76-7E5532D03B8DQ37423705-A12699DC-E075-45F6-8651-2F594D1F753AQ37939221-2D45EDAD-52AA-465A-9065-A4CEDC67A9CFQ38031324-D45CCD1C-2EBB-493A-8D99-E6FAFDA23B5AQ38091323-BCB8D117-4C82-48BF-8651-C4A46F7E7E6FQ38291371-43F224DD-555D-48AC-BC1E-D3699898622DQ38383926-4609D955-B48C-44CA-AE98-153F26FCE6F5Q39274236-D4174F7B-24ED-4CF0-B891-B42B5E5C6547Q40361236-7D2EF561-4889-40D1-A5B3-D55B887A2A9AQ41981820-83D00184-68EA-48DE-8B71-952336CCD55CQ43042829-5F966B7E-5E3E-4C9F-994A-B221AEBF7224Q44740214-123F9CCA-C51F-4B8A-8B95-0477C2C4F302Q45159165-7DFEFCBF-B0D5-4DE1-9B4C-9D221B3272E0Q46798751-299B9302-776A-4EC1-9358-FEA128B6CC28Q46913592-FDDDC26B-2095-4D18-BE55-D977DE905AC2
P2860
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@ast
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@en
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@nl
type
label
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@ast
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@en
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@nl
prefLabel
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@ast
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@en
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@nl
P2093
P2860
P356
P1476
Escitalopram in the treatment ...... ntrolled, flexible-dose study.
@en
P2093
Andrew Korotzer
Anjana Bose
Hongjie Zheng
Jonathan R T Davidson
P2860
P304
P356
10.1002/DA.10146
P577
2004-01-01T00:00:00Z